We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+18.95%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$11.5B
AUM Growth
+$2.07B
Cap. Flow
+$618M
Cap. Flow %
5.37%
Top 10 Hldgs %
60.42%
Holding
101
New
16
Increased
10
Reduced
10
Closed
17

Top Buys

Rank Stock Value
1
PBLS
Parabilis Medicines Inc
PBLS
+$799M
2
COAG
Hemab Therapeutics
COAG
+$215M
3
ABVX
Abivax
ABVX
+$128M
4
ORKA
Oruka Therapeutics
ORKA
+$104M
5
ARTV
Artiva Biotherapeutics
ARTV
+$73.8M

Top Sells

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$219M
2
NUVL
Nuvalent
NUVL
+$138M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$120M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$84.9M
5
SYRE icon
Spyre Therapeutics
SYRE
+$81.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.67%
2 Financials 0.27%
3 Miscellaneous 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLAB icon
26
Zai Lab
ZLAB
$2.93B
$109M 0.95%
5,743,533
+36,271
+0.6% +$717K
SPRY icon
27
ARS Pharmaceuticals
SPRY
$586M
$87M 0.76%
10,860,977
– –
XNCR icon
28
Xencor
XNCR
$1.94B
$84.9M 0.74%
5,274,274
+377,037
+8% +$4.71M
JBIO
29
Jade Biosciences
JBIO
$1.33B
$81.6M 0.71%
3,671,083
– –
NTLA icon
30
Intellia Therapeutics
NTLA
$1.8B
$76.6M 0.67%
+4,526,926
New +$63.4M
LBRX
31
LB Pharmaceuticals
LBRX
$1.54B
$71.7M 0.62%
2,208,604
– –
DFTX
32
Definium Therapeutics
DFTX
$5.51B
$70.6M 0.61%
+1,500,000
New +$37.1M
ACRS icon
33
Aclaris Therapeutics
ACRS
$885M
$67.3M 0.58%
12,723,026
+5,918,954
+87% +$26.4M
FDMT icon
34
4D Molecular Therapeutics
FDMT
$810M
$67.2M 0.58%
5,049,779
– –
SANA icon
35
Sana Biotechnology
SANA
$1.18B
$65.4M 0.57%
+18,750,000
New +$60.4M
DMRA
36
Damora Therapeutics
DMRA
$1.79B
$62.4M 0.54%
2,399,702
+392
+0% +$9.49K
MNPR icon
37
Monopar Therapeutics
MNPR
$751M
$61.8M 0.54%
667,207
– –
ABOS icon
38
Acumen Pharmaceuticals
ABOS
$211M
$56.1M 0.49%
20,992,669
– –
GERN icon
39
Geron
GERN
$970M
$54.8M 0.48%
42,809,751
-20,961,615
-33% -$29.5M
RZLT icon
40
Rezolute
RZLT
$445M
$49.1M 0.43%
9,445,039
+265,039
+3% +$984K
EVMN
41
Evommune Inc
EVMN
$480M
$46.4M 0.4%
3,494,638
– –
VOR icon
42
Vor Biopharma
VOR
$1.34B
$44.2M 0.38%
2,402,095
-3,002,903
-56% -$45.4M
IPSC icon
43
Century Therapeutics
IPSC
$366M
$43.5M 0.38%
17,754,430
– –
AKTS
44
Aktis Oncology
AKTS
$1.43B
$42.4M 0.37%
1,314,405
-188,679
-13% -$3.88M
BIOA
45
BioAge Labs
BIOA
$443M
$41M 0.36%
1,671,648
+21,000
+1% +$379K
CCCC icon
46
C4 Therapeutics
CCCC
$474M
$37.4M 0.32%
8,000,000
– –
MIRM icon
47
Mirum Pharmaceuticals
MIRM
$5.94B
$37.3M 0.32%
318,554
– –
CAPR icon
48
Capricor Therapeutics
CAPR
$558M
$36.3M 0.32%
1,507,844
– –
PEPG icon
49
PepGen
PEPG
$213M
$36.1M 0.31%
20,064,545
– –
PRLD icon
50
Prelude Therapeutics
PRLD
$437M
$34.5M 0.3%
+6,475,882
New +$28.2M
1
2
3 4 5

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, RA Capital Management held 101 positions worth $11.5B, up 22% from $9.44B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

RA Capital Management deployed $618M of net new capital in Q2 2026, opening 16 new positions and adding to 10 existing holdings. Its largest new stake was Parabilis Medicines Inc: 28,933,371 shares worth $792M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Nuvalent, an estimated $138M trimmed.

  • RA Capital Management's largest Q2 2026 buy was Parabilis Medicines Inc: 28,933,371 shares worth $792M.
  • RA Capital Management added most to Artiva Biotherapeutics in Q2 2026, an estimated $73.8M increase.
  • RA Capital Management's biggest Q2 2026 reduction was Nuvalent, cutting an estimated $138M.
  • RA Capital Management fully exited Dianthus Therapeutics in Q2 2026, selling an estimated $219M.
  • RA Capital Management's ten largest holdings make up 60% of its $11.5B portfolio in Q2 2026.
  • RA Capital Management opened 16 new positions and closed 17 in Q2 2026.
  • RA Capital Management's portfolio value rose 22% quarter-over-quarter to $11.5B.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.